Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study
Therapeutic Advances in Endocrinology and Metabolism · 2026-03 · 17
DOI: 10.1177/20420188261442014 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Therapeutic Advances in Endocrinology and Metabolism, online erschienen am 18.04.2026. Verfasst von Hui-Hsia Hsieh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science and Technology Council, Taiwan, R.O.C., Chang Bing Show Chwan Memorial Hospital, China Medical University Hospital.
Abstract (Originalsprache)
Background
The causes of cardiovascular disease are complex, with hyperlipidemia being a major factor in its development. The connection between peptic ulcer disease (PUD) and hyperlipidemia is unclear, and there have been no thorough studies on the effect of anti-PUD medications on the risk of hyperlipidemia, particularly in Asian populations. This study aimed to explore the relationship among PUD, anti-PUD medications, and the risk of developing hyperlipidemia.
Objectives
Utilizing a population-based cohort study conducted in Taiwan, we investigated the association between PUD, the administration of anti-PUD medications, and the subsequent risk of developing hyperlipidemia.
Design
Retrospective study.
Methods
Using data from the Taiwan National Health Insurance Research Database, we conducted a 21-year follow-up study on patients diagnosed with PUD between 2000 and 2021. The Cox proportional hazards regression model was used to analyze the risk of developing hyperlipidemia in relation to PUD and the use of anti-PUD medications.
Results
According to the multivariable Cox proportional hazards regression analysis, patients with PUD had a higher overall incidence of hyperlipidemia (80.7 vs 53.6 per 1000 person-years) than those without PUD. The adjusted hazard ratio was 1.64 (95% confidence interval = 1.62–1.67). Both men and women, as well as different age groups, showed a higher risk of hyperlipidemia among patients with PUD. Patients with PUD who undergo surgery have a higher risk of developing hyperlipidemia than those who do not. The use of anti-PUD medications, such as H2 receptor antagonists, proton pump inhibitors, antibiotics, prostaglandin analogs, anticholinergics, antacids, and carbenoxolone, but not bismuth salts, was associated with a lower risk of developing hyperlipidemia than non-use.
Conclusion
Patients with PUD were more likely to develop hyperlipidemia. However, patients receiving anti-PUD medications had a lower incidence of hyperlipidemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.
- Department of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan.
- Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
- Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.
- School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.
- Division of Medical Genetics, China Medical University Children's Hospital, Taichung, Taiwan.
ORCID-Profile: Yun-Ping Lim
Förderung
- National Science and Technology Council, Taiwan, R.O.C.
- Chang Bing Show Chwan Memorial Hospital
- China Medical University Hospital
- Buddhist Tzu Chi Medical Foundation
- China Medical University, Taiwan
Zitieren
APA
Hsieh, H. H., Lee, W. Y., Lin, C. L., Chen, C. H., Tsai, F. J., You, B. J., Tien, N., Fang, Y. J., & Lim, Y. P. (2026). Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study. Therapeutic Advances in Endocrinology and Metabolism, 17. https://doi.org/10.1177/20420188261442014
Vancouver
Hsieh HH, Lee WY, Lin CL, Chen CH, Tsai FJ, You BJ, et al. Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study. Therapeutic Advances in Endocrinology and Metabolism. 2026;17. doi:10.1177/20420188261442014
BibTeX
@article{Hsieh2026,
author = {Hsieh, Hui-Hsia and Lee, Wan-Yi and Lin, Cheng-Li and Chen, Chi-Hua and Tsai, Fuu-Jen and You, Bang-Jau and Tien, Ni and Fang, Yi-Jen and Lim, Yun-Ping},
title = {Impact of anti-peptic ulcer disease (PUD) medications on hyperlipidemia risk in patients with PUD: a population-based retrospective cohort study},
journal = {Therapeutic Advances in Endocrinology and Metabolism},
year = {2026},
volume = {17},
doi = {10.1177/20420188261442014}
}
EUVIMED